What is the appropriate adult dosing regimen for amikacin injection, including renal function adjustments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Amikacin Adult Dosing

For adults with normal renal function, administer amikacin 15 mg/kg/day (maximum 1.0 g/day) intramuscularly or intravenously as a single daily dose, with dose reduction to 10 mg/kg/day (750 mg) for patients over 59 years of age. 1

Standard Dosing Regimens

Normal Renal Function

  • Initial dosing: 15 mg/kg/day IM or IV, divided as either:
    • 7.5 mg/kg every 12 hours, OR
    • 5 mg/kg every 8 hours 1
  • Maximum daily dose: 1.5 g/day (do not exceed 15 mg/kg/day total) 1
  • Age adjustment: Reduce to 10 mg/kg/day (750 mg maximum) for patients >59 years 2, 3

Alternative Dosing for Specific Indications

For non-tuberculous mycobacterial (NTM) infections, more aggressive dosing may be warranted:

  • Daily dosing: 15 mg/kg once daily or 7.5 mg/kg twice daily
  • Intermittent dosing: 15-25 mg/kg three times weekly 4
  • For cystic fibrosis patients with NTM: 10-30 mg/kg once daily or 15 mg/kg/day in two divided doses, with flexibility for daily to 3× weekly dosing 5

For drug-resistant tuberculosis, the regimen follows a phased approach:

  • Initial phase: 15 mg/kg/day (maximum 1.0 g) as single daily dose, 5-7 days/week
  • Continuation phase: Reduce to 2-3 times weekly after first 2-4 months or after culture conversion 2, 3

Renal Impairment Adjustments

Critical principle: In renal insufficiency, maintain the milligram dose at 12-15 mg/kg but reduce dosing frequency to preserve concentration-dependent bactericidal activity. 2, 3

Dosing Interval Extension Method

  • Calculate dosing interval (hours) = serum creatinine (mg/dL) × 9
  • Example: If serum creatinine = 2 mg/dL, give 7.5 mg/kg every 18 hours 1

Dose Reduction Method

For patients requiring fixed intervals with renal impairment:

  1. Give loading dose of 7.5 mg/kg
  2. Calculate maintenance dose:
    • Maintenance dose = (observed CrCl / normal CrCl) × calculated loading dose
    • Administer every 12 hours 1

Alternative simplified approach: Divide normally recommended dose by patient's serum creatinine value 1

Hemodialysis Patients

  • Maintain dose at 12-15 mg/kg per dose
  • Reduce frequency to 2-3 times weekly
  • Administer after dialysis to facilitate directly observed therapy and avoid premature drug removal 2, 3

Intravenous Administration

  • Dilute 500 mg vial in 100-200 mL of sterile diluent (0.9% NaCl or 5% dextrose)
  • Infusion duration:
    • Adults: 30-60 minutes 1
    • Infants: 1-2 hours 1
  • Total daily dose identical to IM dosing 1

Therapeutic Drug Monitoring

Mandatory monitoring parameters to minimize nephrotoxicity and ototoxicity:

Target Concentrations

  • Peak (Cmax):
    • Daily dosing: 25-35 mg/L (measure 30-90 minutes post-infusion) 4
    • Three times weekly: 65-80 mg/L 4
    • Avoid peaks >35 mcg/mL 1
  • Trough:
    • <5 mg/L (ideally <2.5 mg/L to minimize toxicity) 4
    • Avoid troughs >10 mcg/mL 1

Monitoring Schedule

  • Peak levels: First week, repeat if poor response 4
  • Trough levels: Weekly for 4 weeks, then fortnightly when stable 4
  • Renal function: Twice weekly during month 1, weekly during month 2, then fortnightly 4
  • Auditory/vestibular: Baseline audiogram, vestibular testing, Romberg testing; monthly assessments with symptom questioning; repeat if eighth nerve toxicity symptoms develop 2, 3

Critical Safety Considerations

Nephrotoxicity Risk Factors

  • Renal impairment was observed in 8.7% of patients receiving amikacin, with higher frequency in those with:
    • Initially elevated creatinine
    • Larger cumulative doses
    • Concurrent nephrotoxic agents 2, 3, 2
  • Amikacin is more nephrotoxic than streptomycin 2, 3, 2

Ototoxicity Risk Factors

  • High-frequency hearing loss occurred in 24% in one report, though literature review found only 1.5% 2, 3, 2
  • Causes primarily deafness with less vestibular dysfunction than streptomycin 2, 3, 2
  • Risk increased with:
    • Concurrent diuretic use
    • Prolonged treatment duration
    • Higher doses
    • Advanced age 2, 3, 2

Absolute Contraindications

  • Pregnancy: Risk of fetal nephrotoxicity and congenital hearing loss 2, 3, 2

Treatment Duration

  • Usual duration: 7-10 days 1
  • If treatment extends beyond 10 days: Re-evaluate necessity and monitor serum levels, renal function, auditory and vestibular function closely 1

Special Populations

Obesity

For markedly obese patients, calculate adjusted dose using:

  • Adjusted body weight = ideal body weight + 0.4 × (actual weight - ideal body weight)
  • Male IBW (kg) = 50 + (2.3 × height in cm above 152.4)/2.54
  • Female IBW (kg) = 45.5 + (2.3 × height in cm above 152.4)/2.54 4

Uncomplicated UTI

  • Alternative regimen: 250 mg twice daily 1

Common Pitfalls to Avoid

  1. Do NOT reduce the milligram dose in renal impairment—only extend the interval to maintain concentration-dependent killing 2, 3
  2. Do NOT physically premix amikacin with other drugs—administer separately 1
  3. Do NOT use fixed dosing without weight-based calculation—toxicity risk increases 1
  4. Do NOT continue beyond 10 days without reassessment and intensified monitoring 1
  5. Do NOT forget age-based dose reduction for patients >59 years 2, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.